254 related articles for article (PubMed ID: 20546778)
1. Recent therapeutic approaches to platelet activation in coronary artery disease.
Tousoulis D; Paroutoglou IP; Papageorgiou N; Charakida M; Stefanadis C
Pharmacol Ther; 2010 Aug; 127(2):108-20. PubMed ID: 20546778
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
4. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
Hoylaerts MF
Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
[TBL] [Abstract][Full Text] [Related]
5. Oral antiplatelet agents in ACS: from pharmacology to clinical differences.
Agewall S; Badimon L; Drouet L; Eschenhagen T; Husted S; Simon T; Steg G
Fundam Clin Pharmacol; 2011 Oct; 25(5):564-71. PubMed ID: 21077944
[TBL] [Abstract][Full Text] [Related]
6. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
7. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
[TBL] [Abstract][Full Text] [Related]
8. Novel antiplatelet strategies in acute coronary syndromes.
Sabatine MS
Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
[TBL] [Abstract][Full Text] [Related]
9. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Anderson SD; Shah NK; Yim J; Epstein BJ
Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
[TBL] [Abstract][Full Text] [Related]
11. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.
Cowley MJ; Kuritzky L
Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337
[TBL] [Abstract][Full Text] [Related]
12. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
15. eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment.
Fatini C; Sticchi E; Bolli P; Marcucci R; Giusti B; Paniccia R; Gori AM; Gensini GF; Abbate R
Platelets; 2009 Dec; 20(8):548-54. PubMed ID: 19891529
[TBL] [Abstract][Full Text] [Related]
16. GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events.
Gardiner EE; Arthur JF; Shen Y; Karunakaran D; Moore LA; Am Esch JS; Andrews RK; Berndt MC
Platelets; 2010; 21(4):244-52. PubMed ID: 20367574
[TBL] [Abstract][Full Text] [Related]
17. [Thrombocyte receptors: current views and therapeutic options].
Peters RJ; Moons AH; Büller HR
Ned Tijdschr Geneeskd; 1999 Sep; 143(39):1952-7. PubMed ID: 10526614
[TBL] [Abstract][Full Text] [Related]
18. Platelet activation and progression to complications.
Kereiakes DJ; Michelson AD
Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
[TBL] [Abstract][Full Text] [Related]
19. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
[TBL] [Abstract][Full Text] [Related]
20. The genetics of antiplatelet drug resistance.
Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
